ArticlePloS one2009
Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 53 citations in OpenAlex.
- A Glycolipidated-liposomal peptide vaccine confers long-term mucosal protection against Streptococcus pyogenes via IL-17, macrophages and neutrophils.Nature communications · 2023Article
- Article
- Article
- M-protein based vaccine induces immunogenicity and protection fromNPJ vaccines · 2020Article
- Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.PloS one · 2020Article
- Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.Scientific reports · 2017Article
- Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.PloS one · 2017Article
- Streptococcal Immunity Is Constrained by Lack of Immunological Memory following a Single Episode of Pyoderma.PLoS pathogens · 2016Article
- Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.Human vaccines & immunotherapeutics · 2016Article
- Article
- Identifying protective Streptococcus pyogenes vaccine antigens recognized by both B and T cells in human adults and children.Scientific reports · 2016Article
- Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination.The AAPS journal · 2015Article
- Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.Journal of immunology research · 2015Review
- The contribution of non-human primate models to the development of human vaccines.Discovery medicine · 2014Article
- Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2013Article
- Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.Clinical and vaccine immunology : CVI · 2012Article
- Cutting edge issues in rheumatic fever.Clinical reviews in allergy & immunology · 2012Review
- Defense from the Group A Streptococcus by active and passive vaccination with the streptococcal hemoprotein receptor.The Journal of infectious diseases · 2011Article
- Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus Strain.Clinical and vaccine immunology : CVI · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Vaccination with J8-DT, a leading GAS vaccine candidate, results in protective immunity in mice. Analysis of immunologic correlates of protection indicated a role of J8-specific antibodies that were induced post-immunization. In the present study, several independent experimental approaches were employed to investigate the protective immunological mechanisms involved in J8-DT-mediated immunity. These approaches included the passive transfer of mouse or rabbit immune serum/antibodies in addition to selective depletion of T-cell subsets prior to bacterial challenge. Passive transfer of J8-DT antiserum/antibodies from mice and rabbits conferred significant resistance against challenge to mice. To exclude the possibility of involvement of other host immune factors, the studies were repeated in SCID mice, which highlighted the need for an ongoing immune response for long-lived protection. Depletion of CD4(+) and CD8(+) T-cell subsets confirmed that an active de novo immune response, involving CD4(+) T-helper cells, is required for continued synthesis of antibodies resulting in protection against GAS infection. Taken together these results indicate an involvement of CD4(+) T-cells in J8-DT-mediated protection possibly via an ability to maintain antibody levels. These results have considerable relevance to the development of a broad spectrum passive immunotherapy for GAS disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.